Clinical Trial Update: Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab [Phase 2]

View source ↗

Summary

A phase 2 trial of Aloxi (palonosetron) for preventing chemotherapy-induced nausea and vomiting in malignant glioma patients receiving irinotecan with bevacizum…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• Aloxi (palonosetron hydrochloride)

Snippet

Sponsor: Duke University | Conditions: Brain Cancer | Phase 2 | Status: TERMINATED | Results posted: 2014-04-01